Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq:AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 10:30 a.m. PT in San Francisco, CA.
Related news for (AVIR)
- Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
- Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
- Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
- Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
- Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025